Paratek Pharmaceuticals Inc (NASDAQ:PRTK) – Equities research analysts at Leerink Swann boosted their Q3 2018 earnings per share (EPS) estimates for Paratek Pharmaceuticals in a research note issued on Wednesday, October 3rd. Leerink Swann analyst A. Fadia now expects that the specialty pharmaceutical company will earn ($0.59) per share for the quarter, up from their previous estimate of ($0.97). Leerink Swann also issued estimates for Paratek Pharmaceuticals’ Q4 2018 earnings at ($1.03) EPS, FY2018 earnings at ($3.47) EPS, FY2019 earnings at ($3.79) EPS, FY2020 earnings at ($2.11) EPS, FY2021 earnings at ($0.87) EPS and FY2022 earnings at $2.08 EPS.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.94) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.02). The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.10 million. Paratek Pharmaceuticals had a negative return on equity of 106.39% and a negative net margin of 1,961.41%.
PRTK has been the topic of a number of other reports. Guggenheim set a $26.00 price objective on Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 3rd. ValuEngine upgraded Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 2nd. Bank of America initiated coverage on Paratek Pharmaceuticals in a research report on Monday, August 27th. They set a “neutral” rating and a $13.00 price objective on the stock. BidaskClub upgraded Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Zacks Investment Research cut Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 3rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $31.50.
PRTK opened at $11.60 on Monday. The company has a market cap of $307.78 million, a PE ratio of -3.52 and a beta of 0.57. The company has a current ratio of 7.88, a quick ratio of 7.88 and a debt-to-equity ratio of 2.37. Paratek Pharmaceuticals has a 1 year low of $9.00 and a 1 year high of $26.10.
A number of large investors have recently made changes to their positions in PRTK. Balter Liquid Alternatives LLC acquired a new position in Paratek Pharmaceuticals in the second quarter worth $137,000. Cubist Systematic Strategies LLC acquired a new position in Paratek Pharmaceuticals in the first quarter worth $147,000. Metropolitan Life Insurance Co. NY boosted its stake in Paratek Pharmaceuticals by 81.4% in the second quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 6,625 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new position in Paratek Pharmaceuticals in the second quarter worth $154,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Paratek Pharmaceuticals in the first quarter worth $162,000. Hedge funds and other institutional investors own 77.31% of the company’s stock.
In other Paratek Pharmaceuticals news, COO Evan Loh sold 8,861 shares of the company’s stock in a transaction on Wednesday, October 3rd. The stock was sold at an average price of $9.82, for a total value of $87,015.02. Following the sale, the chief operating officer now directly owns 235,286 shares in the company, valued at $2,310,508.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Adam Woodrow sold 8,750 shares of the company’s stock in a transaction on Wednesday, October 3rd. The shares were sold at an average price of $9.82, for a total value of $85,925.00. Following the completion of the sale, the vice president now owns 112,917 shares in the company, valued at $1,108,844.94. The disclosure for this sale can be found here. Insiders sold 41,503 shares of company stock worth $407,559 over the last quarter. Company insiders own 6.20% of the company’s stock.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
See Also: Outstanding Shares
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.